Factor VII Deficiency: Diagnosis and Management
Diagnosis
Factor VII deficiency is diagnosed by an isolated prolonged prothrombin time (PT) with a normal activated partial thromboplastin time (aPTT), followed by specific Factor VII coagulant activity (FVII:C) assay. 1, 2
Diagnostic Algorithm
First-line testing: PT and aPTT are performed in all patients with suspected bleeding disorders 3
- PT will be prolonged while aPTT remains normal—this is the only congenital bleeding disorder with this pattern 2
Confirmatory testing: Specific FVII:C assay to quantify factor VII levels 4, 2
- Severe deficiency: FVII:C <1%
- Moderate deficiency: FVII:C 1-5%
- Mild deficiency: FVII:C 5-20% 5
Molecular diagnosis: FVII gene sequencing can identify specific mutations on chromosome 13, though this is typically second-line testing 4, 2
Critical Diagnostic Pitfall
There is no consistent correlation between FVII:C levels and bleeding severity—some patients with undetectable FVII may be asymptomatic, while others with 10-15% levels may bleed significantly. 4, 2 Clinical phenotype must guide management decisions, not laboratory values alone. 1
Management of Acute Bleeding
Recombinant activated factor VII (rFVIIa) is the primary treatment for acute bleeding episodes in Factor VII deficiency. 1
Dosing for Acute Bleeding
- Standard dose: 15-30 mcg/kg every 4-6 hours until hemostasis is achieved 6, 1
- Most bleeding episodes respond to single "intermediate" doses (median 60 mcg/kg) 5
Treatment Duration by Bleeding Type
Hemarthroses, muscle/subcutaneous hematomas, epistaxis, gum bleeding: Single-day replacement therapy is typically sufficient 5
Menorrhagia: Single or multiple-dose schedules lead to favorable outcomes 5
Life-threatening bleeds (CNS, gastrointestinal): Require prolonged treatment courses and consideration of short- or long-term prophylaxis 5
Alternative Therapies When rFVIIa Unavailable
Fresh frozen plasma (FFP): Requires large volumes (20 mL/kg initially, then 3-6 mL/kg maintenance) with risks of transfusion-associated circulatory overload and TRALI 7, 1
Plasma-derived FVII concentrates: Effective alternative when rFVIIa is not accessible 8, 1
Prothrombin complex concentrates (PCCs): Can be used but contain variable FVII content and carry thrombotic risk 9
Perioperative Management
For surgical procedures, administer rFVIIa 15-30 mcg/kg immediately before surgery and continue every 4-6 hours throughout the perioperative period. 1
Surgical Prophylaxis Protocol
- Pre-operative dose: 15-30 mcg/kg given immediately before incision 6, 1
- Intraoperative: Continue dosing every 4-6 hours 1
- Post-operative: Maintain treatment until wound healing is secure 8
- Target levels: Aim to maintain FVII activity sufficient for hemostasis, though laboratory monitoring is not validated for determining therapeutic adequacy 10, 1
Clinical assessment of hemostasis must guide management as no validated laboratory tests exist to determine therapeutic levels. 10, 1
Long-term Prophylaxis Indications
Prophylactic treatment should be initiated for specific high-risk populations. 8, 1
Who Requires Prophylaxis
Newborns with severe deficiency: High risk of early gastrointestinal and CNS bleeding 8, 1
Patients with history of severe bleeding: Particularly those with recurrent CNS hemorrhage, severe hemarthroses, or surgery-related bleeding 8, 1, 5
Women with severe menorrhagia: Those with bleeding refractory to other measures 8, 1
Safety Considerations and Monitoring
Thrombotic Risk
Exercise caution in patients with prothrombotic risk factors including advanced atherosclerotic disease, crush injury, septicemia, or DIC where tissue factor may be expressed. 10, 1
- Thrombotic events have been reported in older patients with cardiovascular risk factors treated with rFVIIa 10
- The risk appears lower in congenital FVII deficiency compared to acquired hemophilia, but vigilance is required 10, 11
Inhibitor Development
Inhibitory antibodies to rFVIIa are rare but have been reported in FVII-deficient patients. 10, 1, 11
- Two inhibitors were detected among repeatedly treated patients in the STER registry (one post-rFVIIa, one post-pdFVII) 5
- Monitor for decreased treatment efficacy suggesting possible inhibitor development 5
Liver Transplantation
Liver transplantation is curative but should be reserved exclusively for the most severely affected patients who fail medical management or experience life-threatening complications. 8, 1
- Medical management with factor replacement is strongly preferred 8
- Transplantation consideration only after documented failure of optimal medical therapy 8, 1
- During transplant surgery, factor replacement is required intraoperatively and for 1-3 days post-operatively 8
Clinical Phenotype Considerations
Women comprise an excess of symptomatic patients, with menorrhagia affecting two-thirds of women of fertile age. 4, 2
Surgery-related bleeding is frequent and often serves as the diagnostic event in previously asymptomatic individuals. 2 This underscores the importance of pre-operative screening in patients with family history or suggestive bleeding history, even if previously asymptomatic.